Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06887101

Impact of Stress on Cardiovascular Events in Patients with Peripheral Arterial Disease

Atherosclerotic cardiovascular disease is the leading cause of morbidity and mortality worldwide. Patients with peripheral arterial disease are at increased risk suffering from major adverse cardiac and limb events. Acute and chronic stress affect the cardiovascular system. Long-term negative stressors lead to cardiovascular diseases and can aggravate already existing cardiovascular diseases. However, current guidelines on cardiovascular disease prevention highlight stress as a cardiovascular risk factor there is a lack of consensus about the definition and measurement of stress. The aim of the proposed trial is to evaluate different stress measuring methods in patients with PAD depending on the occurrence of cardiovascular events.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen

Essen, 45147, Germany

Location status: Recruiting

Location contact

Julia Lortz, MD

CONTACT

[email protected]

+49201723-84995

About this study

Based on World Health Organization data, atherosclerotic cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Peripheral arterial disease (PAD) is a poly-vascular disease in multiple arterial beds mostly associated with high atherosclerotic burden. It is estimated that around 50 million people in Europe alone suffer from PAD and the prevalence increases with age. The cause of CVD, such as PAD, coronary artery disease (CAD) or cerebrovascular disease, is atherosclerosis, a systemic chronic inflammatory vascular disease. Patients with CVD are at increased risk of life-threatening complications such as acute limb events, stroke and myocardial infarction combined with an impaired quality of life.

Acute and chronic stress affect the cardiovascular system. Numerous studies have shown the relationship between chronic stress and cardiovascular diseases. On the one hand, permanent negative stressors lead to cardiovascular diseases via different pathways such as the hypothalamic-pituitary-adrenal (HPA) axis or the autonomic nervous system, and, on the other hand, stress can aggravate an already existing CVD. In addition, cardiovascular risk factors like hypertension and hypercholesteremia are negatively influenced by stress. Stress as a cardiovascular risk factor is receiving increasing attention, leading to its recognition in current guidelines on cardiovascular disease prevention.

Due to the demographic development of an ageing population and the simultaneous increase in atherogenic risk factors, a further rise of patients with CVD will be expected in the future. Thus, sufficient assessment of cardiovascular risk in patients with PAD and adequate stress evaluation are elementary. However, there is a lack of consensus about the definition and measurement of stress.

Therefore, the investigators aim to evaluate and compare the efficiency of different stress measuring methods depending on the occurrence of major adverse cardiovascular events (MACE) and major adverse limb events (MALE) in patients with PAD.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of lower extremity PAD based on:

  • Limb bypass surgery or
  • aorta-femoral bypass surgery or
  • percutaneous transluminal angioplasty revascularization of the iliac or infrainguinal arteries or
  • limb or foot amputation for arterial vascular disease or
  • intermittent claudication and one or more of either an ankle brachial index (ABI) of less than 0.90 or a peripheral artery stenosis (≥50%) documented by angiography or duplex ultrasound or carotid revascularization or asymptomatic carotid artery stenosis of at least 50% diagnosed by duplex ultrasound or angiography

Exclusion criteria

  • atrial fibrillation
  • high premature ventricular contractions burden
  • pacemaker with constant ventricular pacing
  • antiarrhythmic drugs class I or III

Treatment and study plan

Primary outcomes

  1. Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), Coronary Heart Disease (CHD) Death, or chronic limb ischemia and amputation

    Time frame: Baseline, after 6 months, after 12 months

    Based on the COMPASS trial MACE and MALE includes the composite of cardiovascular death, myocardial infarction, acute limb ischaemia, chronic limb ischaemia and amputation. MACE and MALE will be evaluated at baseline and after 6 and 12 months

  2. Pychological stress

    Time frame: Baseline, after 6 months, after 12 months

    Pychological stress is evaluated by a composite psychometric measure of stress level by using a mean rank at baseline and after 1 year. It is based on a published RCT by Blumenthal et al. and includes the Beck Depression Inventory II (BDI-II), State-Trait Anxiety inventory (STAI), Patient-Reported Outcomes Measurement Information System (PROMIS) Anger, General Health Questionnaire (GHQ) and Perceived Stress Scale (PSS). A range from 1 to 147 was present with higher scores suggestive of better function

  3. Heart rate variability (HRV)

    Time frame: Baseline, after 6 months, after 12 months

    Heart rate variability (HRV) is an indirect marker of autonomic nervous system activity and describes the oscillations between the R-R intervals in the electrocardiogram. It allows a relatively superficial insight into the heart-brain interaction and reflects the psycho-emotional status such as stress or anxiety. According to the guidelines we chose a short-time HRV with 5 minutes of recording

  4. Proinflammatory mediators - IL-6

    Time frame: Baseline, after 6 months, after 12 months

    IL-6 is measured in pg/ml. Standard value is under 2.7 pg/ml. Higher values indicate an increased stress level

  5. Proinflammatory mediators - IL-1ß

    Time frame: Baseline, after 6 months, after 12 months

    IL-1ß is measured in pg/ml. Standard value is under 5 pg/ml. Higher values indicate an increased stress level

  6. Proinflammatory mediators - TNFalpha

    Time frame: Baseline, after 6 months, after 12 months

    TNFalpha is measured in pg/ml. Standard value is under 2.8 pg/ml. Higher values indicate an increased stress level

  7. Proinflammatory mediators - hsCRP

    Time frame: Baseline, after 6 months, after 12 months

    High sensitive-c-reactive protein (hsCRP) is measured in mg/dl. Standard value is under 0.02 mg/dl. Higher values indicate an increased stress level

  8. Hair cortisol concentration

    Time frame: Baseline, after 6 months, after 12 months

    Hair cortisol is reliable biomarker of chronic stress that offers a retrospective non-invasive measurement of long-term HPA-axis activity over several weeks or months. The cortisol concentration, measured in pg/ml, of a 3 cm hair segment using liquid chromatography tandem mass spectrometry will be analyzed. Higher values indicate an increased stress level

Secondary outcomes

  1. Health-related quality of life

    Time frame: Baseline, after 6 months, after 12 months

    We will apply two instrument to measure health-related quality of life. Namely the Short Form-36 health questionnaire and the European Quality of Life 5 Dimensions 5 Level survey (EQ-5D-5L). The SF-36 is an eight-dimensional scale consisting of 36 items. It assesses health-related quality of life based on physical, social, and psychological functioning, role behavior due to physical and psychological functional impairment, physical pain, general health perception, and vitality. The EQ-5D-5L consists of five health-related dimensions that can be assessed at five levels. In addition, the questionnaire contains a visual analog scale for assessing general health

  2. Ankle-brachial index (ABI)

    Time frame: Baseline, after 6 months, after 12 months

    The lower systolic ankle pressure is set in relation to the systolic blood pressure of the upper extremity. The lowest calculated ABI will be used. Normal values are 0.9 to 1.2. ABI values below 0.9 are indicative of PAD, with an ABI below 0.5 showing severe limb ischaemia

  3. Changes in functional capacity

    Time frame: Baseline, after 6 months, after 12 months

    Changes in functional capacity will be recorded using the established 6-minute walk test

  4. LDL-Cholesterol

    Time frame: Baseline, after 6 months, after 12 months

    Low density lipoprotein (LDL) is measured in mg/dl

  5. Serum-cortisol

    Time frame: Baseline, after 6 months, after 12 months

    Serum-Cortisol is measured in mol/l

  6. Depression symptoms (BDI-II)

    Time frame: Baseline, after 6 months, after 12 months

    The BDI-II is a self-report questionnaire comprising 21 items that assess depression severity. Its reliability and validity have been established through various studies among diverse populations and cultural backgrounds. Higher scores indicates increased depression symptoms

  7. Anxiety symptoms (STAI)

    Time frame: Baseline, after 6 months, after 12 months

    The STAI is the most authoritative tool for assessing anxiety in adults, precisely distinguishing between transient "state anxiety" and persistent "trait anxiety". The STAI measures anxiety with 20 items and has a range of 20 to 80. A higher score indicates more pronounced anxiety.

  8. PROMIS-Anger Scale

    Time frame: Baseline, after 6 months, after 12 months

    The PROMIS Anger scale comprises eight items that evaluate various aspects of anger. Scores on the scale range from 8 to 40, with higher scores indicating greater levels of anger

  9. GHQ

    Time frame: Baseline, after 6 months, after 12 months

    The GHQ assesses general distress and consists of 12 items. Respondents' scores range from 0 to 36, where higher scores correspond to increased distress

  10. Perceived Stress Scale

    Time frame: Baseline, after 6 months, after 12 months

    The Perceived Stress Scale-10 item version is a short tool for the assessment of how individuals perceive stress in their lives. The values range from 0 to 40. Higher values indicate higher perceived stress.

    (l) In-treatment assessments: at the start of each intervention module (weekly), the following assessment instruments will be applied: Distress Thermometer (DT), Patient Health Questionnaire-4 (PHQ-4) and self-generated measures to assess coping skills and self-efficacy

Study contacts

Contact information is provided by the study sponsor or research team.

Julia Lortz, MD

CONTACT

[email protected]

+49201723-84995

Sponsors and collaborators

Lead sponsor

University Hospital, Essen

Other

Collaborators

  • Universität Duisburg-Essen

Registry information

Important dates

Study start
2023
Primary completion
2025
Study completion
2026
First posted
Mar 20, 2025
Registry last updated
Mar 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.